Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors

Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, Hyunwoo Kwon, Kenneth Chian, Adam Khorasanchi, Yizhen Guo, Lai Wei, Lingbin Meng, Yuanquan Yang, Asrar Alahmadi, Regan M Memmott, Jacob Kaufman, Kai He, Peter G Shields, Thomas A Mace, Mitch A Phelps, Christopher C Coss, Zihai Li, Kari L Kendra, David P Carbone, Gregory A Otterson, Carolyn J Presley, Dwight H Owen · 2026

Read Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors by Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, Hyunwoo Kwon, Kenneth Chian, Adam Khorasanchi, Yizhen Guo, Lai Wei, Lingbin Meng, Yuanquan Yang, Asrar Alahmadi, Regan M Memmott, Jacob Kaufman, Kai He, Peter G Shields, Thomas A Mace, Mitch A Phelps, Christopher C Coss, Zihai Li, Kari L Kendra, David P Carbone, Gregory A Otterson, Carolyn J Presley, Dwight H Owen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13280536.txt.

Description

Mingjia Li and colleagues report a 2026 cohort study of obesity, sex, comorbidities and survival in cancer patients on immune checkpoint inhibitors. Immune checkpoint inhibitors free the immune system to attack cancer, but obesity impact on their outcomes is poorly understood. The cohort involved six hundred eighty eight patients with metastatic cancer who got the inhibitors as first or second line therapy. Obesity was assessed using body mass index. Cox models and Kaplan Meier analysis examined survival associations.

Patients with higher BMI had longer overall survival, with a hazard ratio for death below one. Sex was examined alongside obesity, given its influence on body composition. Medical comorbidities were weighed in the models as joint predictors. The obesity paradox pattern, where higher weight links to better immunotherapy survival, appears in this cohort. Comorbidity burden may modify the link, so weight alone should not guide inhibitor care.

Catalog record

CREATORMingjia Li, Daniel J Spakowicz, Songzhu Zhao, Hyunwoo Kwon, Kenneth Chian, Adam Khorasanchi, Yizhen Guo, Lai Wei, Lingbin Meng, Yuanquan Yang, Asrar Alahmadi, Regan M Memmott, Jacob Kaufman, Kai He, Peter G Shields, Thomas A Mace, Mitch A Phelps, Christopher C Coss, Zihai Li, Kari L Kendra, David P Carbone, Gregory A Otterson, Carolyn J Presley, Dwight H Owen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE23129
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13280536

Browse the full library · About the Tower of Babel